Duration of Immunomodulator Treatment in Multiple Sclerosis

Introduction to Treatment Duration

The American Academy of Neurology recommends that immunomodulators should be continued indefinitely in patients with multiple sclerosis who demonstrate clinical and radiographic stability, as discontinuation exposes patients to unnecessary risk of disease reactivation and breakthrough activity 1, 2

For patients with Relapsing-Remitting MS (RRMS), treatment should be continued long-term without a predetermined stopping point when patients achieve clinical stability, radiographic stability, stable functional status, and good tolerability of the medication 1
Patients achieving clinical remission should continue therapy for at least 12 months after remission before considering any tapering, with prolonged remission off medication more likely when treatment extends beyond 12 months of clinical remission 3

High-efficacy therapies like ocrelizumab demonstrate sustained benefit, with a 39% reduction in relapse rate maintained at 96 weeks, a 40% reduction in disability progression at 96 weeks, and no new safety signals emerging over ≥7.5 years of treatment 1
Discontinuation of effective therapy risks disease reactivation, with switching to alternative therapy requiring washout periods that risk breakthrough disease activity, and disease reactivation commonly occurring after stopping effective therapy 1, 2

MRI surveillance should be performed every 3-4 months for high-risk patients, every 6 months in the first year, then annually if stable, with diffusion-weighted imaging for PML monitoring in high-risk patients 2
Clinical monitoring should include regular neurological assessments, cognitive assessment every 6 months, and safety monitoring specific to the agent used 2, 4

Treatment modification should be considered if there is a suboptimal response to current therapy, with new relapses, new or enlarging T2 lesions on MRI, gadolinium-enhancing lesions, or sustained EDSS progression 2
Autologous hematopoietic stem cell transplantation (AHSCT) should be considered for relapsing MS refractory to high-efficacy DMT 2

For natalizumab, JC virus antibody testing is required before initiation and every 6 months, with brain MRI every 3-4 months if treatment duration ≥18 months 2
For ocrelizumab, live-attenuated vaccines are contraindicated during treatment, with common adverse events including infusion-related reactions, nasopharyngitis, and urinary/upper respiratory tract infections 1